patient
chronic
obstruct
pulmonari
diseas
copd
often
breathless
despit
optim
medic
care
pulmonari
rehabilit
breathless
frequent
becom
disabl
copd
advanc
may
precipit
hospitalis
proactiv
manag
breathless
may
improv
patient
outcom
describ
develop
multidisciplinari
md
nonpharmacolog
breathless
clinic
patient
copd
literatur
review
evidencebas
nonpharmacolog
treatment
breathless
undertaken
two
randomis
control
trial
rct
report
md
clinic
england
focus
nonpharmacolog
intervent
breathless
travel
grant
enabl
visit
clinic
meet
clinician
identifi
assess
paramet
treatment
option
outcom
measur
return
australia
framework
clinic
refin
rang
resourc
develop
includ
breathless
dvd
relax
cd
acquisit
afford
effect
handheld
fan
pedomet
order
evalu
servic
rct
design
eightweek
waitlist
control
ensur
evalu
plan
standardis
rigor
clinic
began
accept
referr
may
team
consist
respiratori
physician
specialist
respiratori
nurs
physiotherapist
occup
therapist
dietitian
clinic
psychologist
target
popul
patient
document
copd
remain
breathless
despit
standard
care
primari
outcom
rct
chronic
respiratori
questionnair
masteri
breathless
subscal
secondari
outcom
includ
breathless
intens
unpleas
confid
manag
breathless
measur
numer
rate
scale
develop
nonpharmacolog
breathless
clinic
patient
copd
result
excit
option
patient
experienc
refractori
breathless
rct
object
assess
benefit
intervent
patient
patient
remain
breathless
may
offer
addit
psycholog
andor
pharmacolog
treatment
wilson
petrushnko
mbb
two
hundr
ninetythre
pleurx
cathet
insert
indic
mpe
bilater
pleural
pleurx
insert
patient
pleural
periton
cathet
insert
simultan
patient
technic
success
rate
achiev
drain
remain
situ
mean
day
rang
day
almost
patient
die
pleurx
cathet
insitu
pleurodesi
achiev
patient
pleurx
remov
without
fluid
accumul
remain
patient
remain
aliv
pleurx
insitu
pleurx
insert
patient
mpe
due
nsclc
breast
gastricesophag
pancreat
ovarian
colorect
adenocarcinoma
unknown
origin
mesothelioma
hepatocellular
carcinoma
sclc
melanoma
bladder
cholangiocarcinoma
renal
cell
carcinoma
angiosarcoma
endometri
alcohol
cirrhosi
othersunknown
complic
drain
insert
includ
wound
infect
block
cathet
fell
outcuff
expos
leakag
drain
site
bowel
injuri
n
cost
per
patient
averag
entir
durat
pleural
periton
pleurx
respect
ongo
hardwar
cost
insert
cost
averag
number
pleural
drainag
bottl
periton
drainag
bag
per
patient
twentynin
twentytwo
respect
studi
demonstr
safe
use
tunnel
pleurx
cathet
patient
present
mpe
insert
subsequ
drainag
reaccumul
effus
ascit
manag
comfort
patient
home
believ
use
pleurx
cathet
consid
first
line
approach
manag
refractori
mpe
respiratori
medicin
middlemor
hospit
auckland
new
zealand
northern
region
allianc
auckland
new
zealand
oncolog
servic
auckland
citi
hospit
auckland
new
zealand
introduct
new
pathway
district
health
board
greater
auckland
region
develop
incorpor
rapid
access
clinic
rac
upfront
petct
scan
consid
potenti
curabl
initi
assess
order
enabl
quicker
lung
cancer
diagnosi
method
pilot
patient
grade
high
suspicion
lung
cancer
seen
rac
spirometri
perform
statu
assess
avail
radiolog
chest
xray
ct
scan
consid
potenti
curabl
surgeri
radiotherapi
litr
ecog
score
advanc
diseas
evid
imag
comorbid
preclud
radic
treatment
receiv
upfront
petct
scan
receiv
standard
ct
scan
alreadi
done
time
pathway
measur
compar
histor
data
region
lung
cancer
databas
period
year
pilot
result
patient
complet
pathway
found
lung
cancer
patient
upfront
petct
scan
confirm
lung
cancer
subsequ
palli
treatment
nonlung
cancer
diagnos
cancer
nodul
follow
metastasi
cancer
patient
petct
scan
later
pathway
subsequ
cur
treatment
median
time
referr
first
treatment
reduc
day
patient
cur
treatment
intent
day
palli
treatment
intent
lar
consequ
includ
pulmonari
hypertens
ph
aim
compar
plasma
marker
oxid
stress
protein
carbonyl
pc
thiol
concentr
two
ild
cohort
expos
intervent
oxygen
versu
medic
air
method
two
previous
describ
ild
patient
cohort
either
signific
sleeprel
hypoxia
sleep
time
spo
exerciseinduc
desatur
spo
walk
test
particip
randomis
doubleblind
shamcontrol
crossov
studi
pair
plasma
sampl
taken
follow
supplement
oxygen
medic
air
usag
either
sleep
increment
cardiopulmonari
exercis
test
sensit
enzymelink
immunosorb
assay
elisa
use
prooxid
pc
detect
antioxid
thiol
quantifi
use
dtnb
assay
plate
method
life
expect
gener
popul
signific
proport
excess
mortal
due
higher
preval
cardiac
metabol
diseas
less
known
preval
respiratori
diseas
group
cross
section
observ
studi
aim
assess
preval
respiratori
diseas
symptom
patient
admit
inpati
mental
health
unit
method
inpati
structur
interview
questionnair
complet
questionnair
includ
selfreport
diagnos
common
diseas
screen
question
design
detect
respiratori
diseas
sleep
disord
breath
spirometri
perform
basi
symptom
smoke
statu
access
primari
care
assess
includ
surrog
marker
comprehens
care
vaccin
statu
result
patient
report
high
rate
respiratori
symptom
includ
wheez
dyspnoea
cough
product
cough
significantli
associ
tobacco
use
p
patient
report
daili
tobacco
use
use
cannabi
least
monthli
ten
patient
spirometri
consist
copd
formal
diagnosi
copd
previous
symptom
suggest
sleep
disord
breath
common
patient
report
wit
apnoeic
episod
sleep
vaccin
rate
low
pneumococc
influenza
vaccin
peopl
smi
high
rate
respiratori
symptom
high
preval
copd
spirometri
half
copd
case
previous
diagnos
suggest
hidden
burden
respiratori
diseas
patient
smi
introductionaim
evid
suggest
asthma
patient
fail
use
inhal
correctli
result
frequent
exacerb
suboptim
educ
health
profession
subsequ
patient
may
contribut
factor
innov
technolog
augment
realiti
access
via
smartphon
applic
function
educ
tool
address
issu
therefor
aim
studi
obtain
health
profession
asthma
patient
key
commun
stakehold
perspect
feasibl
augment
realiti
technolog
improv
asthma
inhal
techniqu
educ
method
patient
inform
poster
display
imag
asthma
inhal
devic
produc
base
exist
evid
base
recommend
resourc
augment
realiti
technolog
utilis
provid
video
demonstr
correct
inhal
techniqu
devic
made
access
via
free
smartphon
applic
twentyon
semistructur
oneonon
interview
health
profession
asthma
patient
key
commun
stakehold
conduct
august
septemb
data
analys
themat
use
triandi
model
interperson
behaviour
interview
asthma
patient
highlight
perceiv
compet
inhal
techniqu
howev
health
profession
key
commun
stakehold
identifi
percept
misguid
poor
inhal
techniqu
facilit
condit
incorrect
inhal
use
suboptim
diseas
manag
deliv
inhal
techniqu
educ
use
augment
realiti
favour
particip
particularli
around
eas
use
abil
visual
display
variou
inhal
techniqu
devic
howev
particip
identifi
barrier
particulalri
use
among
elderli
augment
realiti
may
novel
mean
address
poor
inhal
techniqu
among
certain
cohort
asthma
patient
serv
prompt
health
profession
initi
review
inhal
devic
randomis
control
trial
design
need
evalu
efficaci
technolog
use
clinic
care
set
introductionaim
peopl
sever
refractori
asthma
sra
like
face
sizeabl
burden
beyond
peopl
milder
diseas
aim
explor
littleknown
experi
peopl
live
sra
method
particip
identifi
sra
via
australasian
sever
asthma
network
andor
specialist
asthma
clinic
across
seven
australian
state
invit
telephon
interview
semistructur
interview
conduct
consecut
new
theme
emerg
interview
record
transcrib
themat
analys
result
particip
age
yr
femal
experienc
daili
symptom
key
theme
bodi
hindranc
sra
place
widerang
limit
life
daili
chore
career
relationship
famili
life
alon
asthma
interviewe
felt
alon
understand
experi
asthma
suffer
emot
distress
includ
frustrat
hopeless
andor
depress
formal
emot
support
servic
lack
strive
adapt
particip
express
vari
degre
adjust
diagnosi
denial
full
accept
concern
experi
treatment
interviewe
accept
need
medicin
concern
oral
corticosteroid
sideeffect
dislik
relianc
treatment
felt
took
life
daytoday
medic
care
particip
report
need
access
knowledg
gp
better
commun
gpsspecialist
acut
care
exacerb
frighten
participantsfamili
yet
avoid
emerg
depart
present
avoid
disrupt
hospitalis
place
daili
live
support
need
practic
emot
support
vari
none
provis
willingfatigu
famili
particip
felt
compel
push
due
parentingfinanci
respons
conclus
sra
impos
longterm
debilit
burden
consid
differ
milder
asthma
urgent
need
improv
support
servic
primari
care
sra
patient
assist
famili
introductionaim
approxim
one
five
patient
attend
gener
practic
daili
smoker
inform
previou
quit
experi
smoke
cessat
prefer
smoker
attend
gener
practic
necessari
inform
effect
intervent
method
currentexsmok
year
pack
year
recruit
gener
practic
across
melbourn
radic
studya
cluster
randomis
control
trial
interdisciplinari
model
care
reduc
burden
smoke
lung
diseas
australian
primari
care
patient
complet
exhal
carbon
monoxid
co
test
confirm
smoke
statu
structur
questionnair
facetofac
interview
result
particip
identifi
across
gener
practic
clinic
melbourn
current
smoker
daili
smoker
median
exhal
co
read
iqr
scale
low
high
selfreport
motiv
median
iqr
confid
quit
median
iqr
modest
among
current
smoker
current
smoker
attempt
quit
previou
month
report
two
attempt
past
year
common
pharmacolog
treatment
use
nicotin
replac
therapi
vareniclin
popular
nonpharmacolog
treatment
hypnotherapi
approxim
smoker
would
use
medic
aid
futur
quit
attempt
ecigarett
use
current
smoker
least
one
quit
attempt
previou
year
would
consid
help
futur
quit
attempt
current
smoker
smoke
among
indigen
peopl
may
potenti
reduc
appropri
intervent
target
prevent
tobacco
smoke
uptak
improv
asthma
manag
undertook
pilot
studi
two
darwin
school
high
proport
indigen
youth
determin
feasibl
innov
peerl
schoolbas
educ
program
call
asthma
smoke
prevent
project
aspp
subset
children
report
persist
respiratori
symptom
also
clinic
evalu
determin
lower
airway
inflammatori
profil
optimis
asthma
manag
aspp
found
evidencebas
program
improv
asthma
manag
prevent
uptak
tobacco
smoke
program
use
studentcentr
approach
senior
student
peer
leader
deliv
aspp
grade
student
use
activ
video
game
student
complet
questionnair
relat
asthma
smoke
baselin
program
deliveri
student
respiratori
symptom
invit
comprehens
clinic
evalu
test
includ
sputum
induct
aspp
well
receiv
student
involv
indigen
complet
baselin
followup
questionnair
selfreport
asthma
high
student
report
smoke
report
exposur
tobacco
home
student
clinic
evalu
indigen
clinic
import
airway
inflamm
high
fraction
exhal
nitric
oxid
level
airway
neutrophilia
airway
eosinophilia
optimis
medic
manag
requir
student
studi
demonstr
feasibl
implement
schoolbas
prevent
intervent
program
atrisk
group
high
preval
clinic
import
airway
inflamm
suboptim
asthma
manag
highlight
need
communitybas
studi
persist
respiratori
symptom
adolesc
reduc
burden
chronic
lung
diseas
particularli
indigen
australian
asthma
allergi
introductionaim
rhinoviru
common
trigger
acut
exacerb
allerg
asthma
airway
epithelium
target
rhinoviru
infect
import
sourc
proinflammatori
antivir
mediat
airway
epitheli
cell
aec
patient
allerg
asthma
exhibit
proinflammatori
phenotyp
aim
characteris
cytokin
environ
allerg
asthma
alter
respons
aec
rhinoviru
investig
signal
pathway
involv
method
cell
welldifferenti
human
airway
epitheli
line
cultur
without
cytokin
hour
stimul
poli
c
agonist
imiquimod
agonist
infect
quantit
realtim
pcr
ncounter
assay
use
characteris
chang
express
mrna
proinflammatori
antivir
mediat
well
viral
patternrecognit
molecul
allerg
cytokin
environ
enhanc
express
mrna
proinflammatori
cytokin
induc
poli
c
imiquimod
express
antivir
respons
gene
induc
poli
c
follow
rhinoviru
infect
cell
pretreat
cytokin
exhibit
significantli
higher
express
cfb
express
either
unchang
modestli
increas
cell
pretreat
cytokin
alter
accompani
increas
express
pattern
recognit
receptor
gene
also
cell
surfac
receptor
rhinoviru
cytokin
appear
promot
increas
product
proinflammatori
mediat
follow
rhinoviru
infect
furthermor
impair
antivir
host
defenc
observ
allerg
asthmat
unlik
due
effect
cytokin
increas
viral
entri
togeth
enhanc
signal
via
rigi
may
gestat
period
day
follow
hypox
exposur
mice
return
normox
environ
second
group
pregnant
mice
hous
normox
condit
throughout
pregnanc
control
group
weight
offspr
record
week
age
point
respons
methacholin
thorac
ga
volum
tgv
assess
iugr
offspr
lighter
birth
compar
control
offspr
week
age
differ
snoutvent
length
abdomin
circumfer
group
week
age
week
airway
resist
methacholin
challeng
greater
male
iugr
offspr
compar
control
femal
iugr
offspr
compar
control
contrast
differ
peripher
lung
mechan
male
iugr
offspr
control
iugr
femal
offspr
increas
tissu
damp
elast
methacholin
challeng
compar
control
differ
tgv
group
matern
hypoxia
induc
iugr
offspr
smaller
birth
exhibit
catch
growth
week
age
physiolog
consequ
iugr
juvenil
period
sex
depend
airway
hyperrespons
male
offspr
impair
peripher
mechan
femal
offspr
sexual
dimorph
respons
iugr
may
contribut
differ
preval
asthma
male
femal
earli
childhood
femal
male
invers
invers
ns
posit
male
femal
ns
ns
posit
invers
male
femal
ns
ns
ns
posit
cytokin
product
independ
associ
sever
variabl
particularli
sex
pdc
number
tnf
product
link
selfreport
cold
frequenc
futur
experi
examin
genet
variant
predict
two
x
chromosom
gene
modifi
cytokin
product
viru
suscept
grant
support
nhmrc
asthma
foundat
qld
astra
zeneca
measur
use
dichotom
variabl
log
transform
dose
respons
slope
logdr
lead
loss
inform
furthermor
regress
logdr
consid
initi
fev
result
estim
difficult
interpret
contrast
linear
mix
model
lmm
standard
biostatist
tool
appear
never
use
bhr
overcom
limit
use
data
collect
produc
intuit
estim
aim
test
util
model
bhr
use
lmm
associ
known
risk
factor
regress
logdr
use
comparison
demonstr
mechan
forc
similar
induc
bronchoconstrict
vivo
induc
product
impair
innat
antivir
immun
primari
human
airway
epitheli
cell
first
time
mechan
forc
shown
impact
innat
immun
data
direct
relev
human
diseas
introductionaim
epithelium
asthmat
differenti
dysregul
may
allow
repair
proper
regener
noxiou
stimuli
eg
virus
allergen
lead
remodel
influenza
viru
one
major
caus
asthma
exacerb
differenti
specif
microrna
eg
may
key
epigenet
factor
involv
aberr
epitheli
cell
differenti
asthmat
upon
exposur
hypothesis
impair
express
epithelium
asthmat
infect
may
link
abnorm
differenti
innat
immun
dysregul
cell
aim
determin
role
primari
bronchial
epitheli
cell
sever
asthmat
determin
target
method
primari
bronchial
epitheli
cell
pbec
sever
asthmat
nonasthmat
subject
cultur
airliquidinterfac
ali
condit
cell
incub
moi
mirna
mrna
isol
use
rnaeasi
mini
kit
modif
subject
taqman
mrna
assay
result
pbec
nonasthmat
asthmat
infect
show
viral
titer
cell
nonasthmat
express
decreas
infect
incresas
recov
basal
level
post
infect
cell
asthmat
express
remain
unchang
infect
express
target
mmp
induc
epigenet
regul
mrna
decreas
infect
cell
nonasthmat
howev
cell
asthmat
express
increas
infect
remain
unchang
despit
similar
level
infect
express
differ
epitheli
cell
asthmat
nonasthmat
infect
reduct
infect
cell
nonasthmat
may
repres
selfdef
mechan
cellular
remodel
copd
link
increas
hospitalis
morbid
notch
famili
receptor
protein
regul
airway
mucu
product
via
differenti
mechan
direct
cell
toward
secretori
ciliat
morpholog
howev
littl
known
notch
role
mucu
product
follow
differenti
aimhypothesi
examin
impact
inhibit
notch
signal
mucu
product
fulli
differenti
primari
bronchial
epitheli
cell
pbec
control
subject
well
patient
asthma
copd
hypothes
notch
inhibit
downregul
mucu
product
method
pbec
donor
cohort
grown
airliquid
interfac
ali
cultur
day
promot
multicellular
differenti
time
cell
treat
dibenzazepin
dbz
potent
inhibitor
notch
signal
apic
line
fluid
collect
everi
assess
releas
complet
experi
sampl
also
collect
protein
mrna
histolog
analysi
result
dbz
treatment
significantli
reduc
express
releas
phenotyp
assess
qpcr
elisa
immunofluoresc
western
blottingqpcr
reveal
signific
reduct
intracellular
domain
mrna
pbec
donor
phenotyp
reduc
express
also
observ
restrict
cell
nonasthmat
follow
treatment
final
goblet
cell
marker
protein
unchang
across
treatment
conclus
notch
inhibit
reduc
express
secret
differenti
pbec
independ
goblet
cell
number
reduct
depend
occur
pbec
control
asthmat
patient
copd
suggest
notch
regul
product
independ
secretori
cell
differenti
decreas
pbec
control
donor
suggest
addit
regul
product
may
compromis
cell
copd
asthma
patient
cigarett
smokeinduc
inflamm
macrophag
initi
inflammasom
involv
signal
hai
b
tran
rhi
hamon
tung
truong
introductionaim
conflict
report
possibl
role
inflammasom
activ
inflamm
copd
hypothes
copd
andor
respons
cigarett
smoke
increas
activ
andor
altern
inflammasom
regul
via
signal
method
human
primari
alveolar
macrophag
macrophag
analys
releas
elisa
cleavageactiv
respons
cigarett
smoke
extract
express
local
asc
recruit
cleav
assess
immunofluorescenceconfoc
microscopi
andor
western
blot
effect
inhibitor
zyvadfmk
antagonist
glyburid
treatment
receptor
regul
without
exposur
cigarett
smoke
extract
investig
alveolar
macrophag
cigarett
smoke
induc
increas
intracellular
express
p
pool
data
donor
particul
stain
cleav
increas
insid
outsid
cell
fold
p
pool
data
particl
partial
coloc
particul
also
increas
macrophag
cigarett
smoke
induc
similar
complex
inhibit
zyvadfmk
glyburid
p
significantli
protect
macrophag
cigarett
smokeinduc
activ
conclus
inflamm
cigarett
smokeexpos
macrophag
initi
inflammasom
former
regul
signal
system
suggest
novel
therapeut
target
copd
hypothesis
profibrot
effect
involv
b
cellmedi
immun
regul
analys
immun
cell
composit
human
lung
biopsi
tissu
examin
effect
b
cell
deplet
bleomycininduc
lung
fibrosi
vivo
result
trend
toward
increas
bcell
activ
factor
april
observ
ipf
patient
serum
versu
age
match
control
addit
observ
increas
number
matur
b
cell
lung
ipf
patient
genet
deplet
b
cell
attenu
bleomycininduc
fibrosi
therapeut
potenti
deplet
follicular
b
cell
use
treatment
assess
mice
given
two
dose
antibodi
provid
genentech
inc
usa
isotyp
control
ip
day
prior
day
bleomycin
extent
fibrosi
measur
day
last
dose
fac
analysi
blood
taken
day
day
postbleomycintreat
reveal
almost
complet
deplet
b
cell
howev
extent
fibrosi
assess
use
microct
imag
hplc
analysi
hydroxyprolin
level
significantli
differ
treatment
group
although
antibodi
deplet
follicular
b
cell
effect
bleomycininduc
fibrosi
residu
b
cell
remain
lung
mice
current
studi
analys
b
cell
subset
fibrot
lung
tissu
mice
ipf
patient
method
primari
human
pulmonari
fibroblast
incub
bsaconjug
fatti
acid
stimul
anoth
releas
measur
use
elisa
act
gener
marker
inflamm
potent
neutrophil
chemoattract
follow
fatti
acid
use
arachidon
acid
aa
eicosapentaeno
acid
epa
palmit
acid
pa
satur
fatti
acid
increas
concentr
result
aa
induc
substanti
p
p
releas
pulmonari
fibroblast
epa
pa
induc
releas
stimul
combin
aa
result
greater
p
p
releas
aa
alon
effect
combin
releas
greater
sum
individu
effect
aa
indic
synergi
find
suggest
dietari
fatti
acid
import
modul
inflammatori
respons
interact
arachidon
acid
result
synerget
inflammatori
respons
pulmonari
fibroblast
could
indic
obes
asthmat
compar
lean
individu
prone
airway
inflamm
high
fat
meal
introductionaim
innat
immun
respons
within
lung
mucosa
instanc
cigarett
smoke
cs
depend
activ
pattern
recognit
receptor
via
multiprotein
complex
call
inflammasom
facilit
matur
releas
proinflammatori
cytokin
interleukin
il
recent
year
plethora
data
clinic
studi
mous
diseas
model
demonstr
excess
inflammasom
activ
promot
sever
diseas
regard
emphysema
major
debilit
compon
copd
shown
link
diseas
despit
observ
causal
role
specif
inflammasom
emphysema
unknown
therefor
aim
reveal
novel
function
link
inflammasom
activ
pathogenesi
emphysema
method
identifi
whether
inflammasom
promot
emphysema
utilis
genet
model
ff
spontan
emphysema
acut
day
csinduc
model
characteris
elev
alveolar
type
ii
cell
atiic
apoptosi
driven
cytokin
demonstr
lung
tissu
emphysema
patient
well
spontan
ff
mice
csinduc
emphysema
mous
model
character
excess
product
gene
encod
form
cytoplasm
dnasens
inflammasom
protein
furthermor
genet
blockad
ff
mice
prevent
develop
emphysema
suppress
augment
atiic
apoptosi
posit
correl
also
exist
elev
mrna
level
mrna
protein
express
level
emphysema
patient
collect
defin
first
time
hyperactiv
endogen
axi
lung
augment
atiic
apoptosi
turn
caus
emphysema
final
believ
studi
also
potenti
aid
futur
therapeut
strategi
target
inflammasom
alon
combin
human
emphysema
introduct
nktlike
cell
repres
bridg
innat
adapt
immun
report
increas
number
steroid
resist
cytotoxicproinflammatori
senesc
null
nktlike
cell
bal
copd
associ
increas
cytotox
bronchial
epitheli
cell
cell
express
drug
efflux
pump
loss
glucocorticoid
receptor
gcr
recent
loss
histon
deacetylas
heat
shock
protein
report
cell
copd
patient
hypothes
molecul
may
decreas
null
nktlike
cell
particularli
subset
method
blood
collect
group
copd
patient
age
match
control
express
gcr
proinflammatori
cytokin
determin
cell
presenc
ae
prednisolon
ae
cyclosporin
bind
complex
ae
theophyllin
follow
cultur
use
flow
cytometri
western
blot
immunofluoresc
result
loss
gcr
express
identifi
null
cell
compar
counterpart
loss
gcr
associ
increas
product
increas
steroid
resist
upregul
gcr
note
presenc
prednisolon
low
dose
cyclosporin
increas
note
presenc
prednisolon
theophyllin
steroid
resist
proinflammatori
null
nktlike
cell
associ
multipl
mechan
combin
prednisolon
lowdos
cyclosporin
theophyllin
treatment
therapi
inhibit
proinflammatori
cytokin
product
cell
may
reduc
system
inflamm
copd
test
effect
bronchodil
alon
exercis
train
ext
combin
standardis
physic
activ
selfmanag
behaviourmodif
bm
programm
exercis
endur
time
eet
patient
copd
randomis
partial
doubleblind
placebo
p
control
parallelgroup
trial
site
australia
new
zealand
usa
canada
europ
intervent
bm
p
tiotropium
olodaterol
week
ext
ext
eet
log
transform
endur
shuttlewalk
test
eswt
symptom
limit
assess
week
primari
end
point
week
result
patient
men
randomis
treat
full
analysi
set
mean
postbronchodil
fev
l
predict
eet
significantli
increas
ext
versu
p
week
figur
patient
reach
test
termin
criteria
minut
without
symptom
limit
p
ext
week
safeti
concern
identifi
shorter
test
twominut
walk
distanc
may
offer
advantag
popul
lack
inform
respons
chang
studi
examin
reliabl
valid
respons
twominut
walk
test
peopl
copd
attend
pulmonari
rehabilit
pr
method
prepr
assess
studi
particip
complet
twominut
walk
test
twice
addit
usual
measur
chronic
respiratori
questionnair
postpr
assess
follow
standard
pr
program
measur
repeat
global
rate
chang
score
obtain
patient
therapist
prepost
program
chang
score
examin
correl
chang
twominut
walk
distanc
use
r
estim
minim
import
differ
anchorbas
method
distributionbas
estim
base
standard
error
measur
examin
testretest
reliabl
icc
bland
altman
agreement
valid
pearson
correl
report
result
preprogram
assess
conduct
particip
year
fev
ae
testretest
reliabl
twominut
walk
distanc
high
mean
differ
trial
ci
two
sixminut
walk
distanc
highli
correl
p
postprogram
assess
complet
patient
ae
year
fev
ae
anchor
clinic
meaning
chang
minim
import
differ
twominut
walk
distanc
area
ci
agre
distributionbas
estim
twominut
walk
distanc
significantli
improv
postprogram
sampl
contrast
qol
measur
conclus
improv
twominut
walk
distanc
least
follow
pr
program
correspond
clinic
meaning
chang
due
learn
effect
first
second
trial
practic
twominut
walk
test
recommend
peopl
chronic
obstruct
pulmonari
diseas
copd
gener
target
generalis
anxieti
depress
randomis
control
trial
aim
determin
whether
ad
cognit
behaviour
therapi
program
sensat
breathless
cbtbreve
comprehens
pulmonari
rehabilit
program
cprp
significantli
improv
health
outcom
beyond
achiev
cprp
alon
method
eight
week
cprp
cycl
repatri
gener
hospit
block
randomis
includ
cbt
breve
social
group
cpr
intervent
peopl
copd
least
moder
airflow
obstruct
fev
pred
fvc
gold
grade
elig
inclus
primari
six
minut
walk
test
hospit
anxieti
depress
scale
had
secondari
outcom
multidimension
dyspnoea
profil
mdp
chronic
respiratori
questionnairecrq
sedentari
physic
activ
accelerometri
actigraph
symptom
score
assess
one
month
one
six
month
post
intervent
particip
feedback
sought
complet
month
assess
differ
group
intent
treat
assess
across
four
assess
point
random
effect
mix
model
result
particip
met
inclus
criteria
signific
p
differ
subject
elig
particip
declin
gold
grade
particip
trial
mean
age
ae
sd
male
fev
pred
ae
preliminari
analysi
indic
statist
clinic
signific
differ
group
assess
point
had
analysi
secondari
outcom
ongo
particip
feedback
uniformli
posit
form
intervent
conclus
despit
overwhelmingli
posit
feedback
cbt
program
combin
cpr
cbt
program
specif
sensat
breathless
result
greater
improv
function
exercis
capac
anxieti
depress
beyond
achiev
standard
cpr
introductionaim
downhil
walk
dw
enhanc
quadricep
contractil
muscl
fatigu
cmf
less
symptom
level
walk
lw
patient
copd
studi
sought
determin
effect
dw
compar
lw
part
comprehens
pulmonari
rehabilit
program
patient
copd
method
copd
patient
fev
pred
randomis
pr
dw
lw
exercis
capac
walk
test
primari
outcom
cycl
endur
test
muscl
function
qualiti
life
assess
program
complet
train
respons
proport
patient
exceed
minim
import
differ
mid
compar
group
via
chi
test
result
magnitud
improv
similar
across
outcom
group
tabl
howev
significantli
greater
proport
patient
dw
exceed
mid
compar
lw
vs
wide
use
evalu
function
exercis
capac
primari
outcom
six
minut
walk
distanc
current
practic
recognis
use
minim
import
differ
mid
key
index
respons
pulmonari
rehabilit
pr
howev
also
provid
inform
dyspnoea
heart
rate
hr
degre
desatur
nadir
p
achiev
test
inform
typic
consid
evalu
patient
outcom
pr
whilst
individu
may
achiev
mid
possibl
indic
may
reflect
improv
aim
studi
compar
chang
peak
dyspnoea
hr
nadir
p
follow
pr
particip
clinic
signific
chang
nonmid
group
achiev
mid
method
data
retrospect
analys
subject
complet
pre
post
pr
year
period
measur
prior
immedi
follow
wk
twice
weekli
pr
program
dyspnoea
borg
scale
hr
record
immedi
end
nadir
p
measur
test
lium
also
process
electron
microscopi
cilia
photograph
ciliari
structur
orient
quantifi
photograph
mannwhitney
u
test
use
analys
differ
ciliari
orient
patient
without
retin
pigmentosa
result
ciliari
beat
frequenc
patient
retin
pigmentosa
normal
mean
ciliari
waveform
uncoordin
video
playback
mean
ciliari
deviat
normal
patient
keep
previous
publish
normal
valu
mean
ciliari
deviat
retin
pigmentosa
patient
consid
almost
random
orient
cilia
cell
surfac
data
demonstr
share
development
link
motil
immotil
cilia
may
help
explain
previous
report
predisposit
respiratori
problem
patient
retin
pigmentosa
airway
cilia
movement
uncoordin
cilia
may
malfunct
due
almost
random
ciliari
orient
clinic
evalu
requir
characteris
respiratori
histori
patient
retin
pigmentosa
introductionaim
audio
characterist
abnorm
paediatr
breath
sound
welldefin
digit
techniqu
captur
wide
investig
studi
aim
defin
audiolog
featur
abnorm
paediatr
breath
sound
object
compar
abil
digit
stethoscop
detect
auscult
use
standard
bellanddiaphragm
stethoscop
method
twenti
children
normal
breath
sound
gener
wheez
crackl
diagnosi
cystic
fibrosi
auscult
paediatr
consult
digit
record
use
digit
electron
stethoscop
digit
stethoscop
use
spectrograph
analysi
record
playback
detect
abnorm
breath
sound
defin
audio
waveform
characterist
result
digit
stethoscop
sensit
standard
auscult
detect
wheez
studi
patient
clinicallydescrib
wheez
period
waveform
segment
increas
intens
frequenc
compar
background
breath
sound
mostli
span
expir
period
second
frequenc
occasion
span
shorter
inspiratori
segment
record
patient
crackl
reveal
brief
millisecond
discontinu
sound
distinguish
waveform
identifi
within
digit
breath
sound
analysi
may
sensit
manual
auscult
detect
breath
sound
abnorm
children
potenti
applic
improv
diagnosi
data
share
diseas
monitor
research
develop
need
aerosolis
corticosteroid
reduc
mouth
throat
deposit
produc
larger
particl
gener
inhal
anecdot
spacer
seldom
use
prescrib
particularli
observ
adolesc
age
group
princess
margaret
hospit
children
perth
recommend
use
spacer
may
necessari
new
asthma
medic
produc
smaller
particl
size
aerosol
aim
assess
effect
particl
size
pmdi
without
spacer
fourteen
adolesc
age
year
mild
stabl
asthma
randomis
use
pmdi
without
spacer
randomis
crossov
studi
radiolabel
tc
corticosteroid
differ
mass
median
aerodynam
diamet
fluticason
propion
becolmethason
diproprion
inhal
use
correct
techniqu
assess
clinic
nurs
specialist
dose
drug
quantifi
immedi
gamma
camera
scan
radiat
detect
quantifi
per
region
interest
account
attenu
bodi
tissu
drug
deposit
lung
orogastr
region
compar
adolesc
inhal
drug
without
spacer
use
wilcoxon
match
pair
signedrank
test
result
fourteen
adolesc
complet
two
visit
without
spacer
observ
signific
differ
qvar
group
lung
deposit
without
spacer
median
vs
flixotid
group
lung
deposit
without
spacer
median
vs
howev
may
power
detect
differ
given
small
sampl
size
dataset
conclus
preliminari
data
suggest
qvar
may
use
without
spacer
adolesc
provid
inhal
techniqu
assess
appropri
train
clinic
profession
would
still
recommend
flixotid
use
spacer
introductionaim
utero
smoke
exposur
associ
abnorm
lung
function
wheez
asthma
infanc
throughout
childhood
neg
influenc
utero
smoke
exposur
modifi
genet
polymorph
gene
import
detoxifi
tobacco
byproduct
includ
glutathion
stransferas
gst
gene
respiratori
antioxid
longterm
effect
utero
exposur
respiratori
health
adulthood
unclear
perth
infant
asthma
follow
studi
longitudin
birth
cohort
subject
recruit
antenat
gener
popul
lung
function
carri
month
year
age
antenat
smoke
histori
collect
parent
recruit
dna
collect
year
subgroup
subject
either
parent
smoke
pregnanc
associ
wheez
ci
asthma
ci
offspr
year
age
thereaft
matern
smoke
pregnanc
associ
reduc
lung
function
offspr
month
mean
vmaxfrc
sd
versu
year
age
mean
predict
sd
versu
later
assess
amongst
children
expos
utero
tobacco
smoke
homozygot
null
genotyp
associ
significantli
lower
lung
function
year
age
compar
nonnul
genotyp
mean
predict
sd
versu
utero
tobacco
smoke
exposur
neg
impact
lung
function
respiratori
symptom
year
age
effect
persist
adulthood
polymorph
antioxid
gene
may
contribut
wors
lung
function
children
expos
utero
tobacco
smoke
fibrosi
cf
inherit
progress
incur
respiratori
condit
caus
signific
morbid
mortal
lung
damag
reflect
spectrum
structur
chang
detect
comput
tomographi
ct
monitor
diseas
progress
guid
therapi
score
system
ct
scan
develop
cf
quantifi
extent
sever
chang
seen
research
examin
structur
lung
chang
ct
scan
use
score
system
deriv
cf
cohort
studi
date
describ
lung
damag
pcd
use
cfderiv
tool
assum
lung
damag
two
condit
ident
potenti
result
failur
identifi
pcdspecif
chang
studi
address
assumpt
method
retrospect
analys
ct
scan
adult
paediatr
patient
pcd
follow
abnorm
found
cf
score
accord
presenc
extent
bronchiectasi
bronchial
wall
thicken
atelectasi
mucou
plug
air
trap
addit
experienc
respiratori
radiologist
review
scan
look
presenc
abnorm
differ
result
bronchial
wall
thicken
common
abnorm
air
trap
least
common
abnorm
present
significantli
often
middl
lower
lobe
compar
upper
lobe
p
valu
present
abnorm
significantli
extens
middl
lower
lobe
compar
upper
lobe
bronchiectasi
mucu
plug
atelectasi
p
air
trap
present
significantli
often
pcd
cohort
respect
cf
cohort
pcduniqu
chang
identifi
dextrocardia
extens
treeinbud
pattern
whole
lobe
atelectasi
interlobar
interlobular
septal
thicken
conclus
signific
structur
chang
seen
ct
scan
patient
pcd
consist
previous
describ
patient
cf
find
illustr
need
develop
pcdspecif
score
system
function
tool
object
assess
diseas
statu
progress
efficaci
therapi
method
patient
undergo
annual
surveil
ct
bronchoalveolar
lavag
bal
includ
assess
structur
lung
diseas
extent
pragmacf
method
develop
grid
overlaid
ct
slice
annot
hierarch
presenc
bronchiectasi
bronchial
wall
thicken
mucou
plug
inspiratori
scan
trap
air
expiratori
scan
overal
diseas
di
trap
air
ta
express
proport
cell
diseas
trap
air
respect
compar
healthi
thirti
scan
randomli
select
rescor
assess
repeat
intraclass
correl
coeffici
icc
linear
mix
model
analysi
use
compar
ct
outcom
presenc
neutrophil
elastas
ne
infect
bal
result
scan
patient
includ
final
analysi
icc
assess
repeat
grade
excel
ct
outcom
associ
presenc
histori
ne
infect
sampl
size
calcul
show
multicentr
clinic
trial
intervent
perform
around
patient
discuss
pragmacf
sensit
tool
monitor
structur
lung
diseas
cf
highli
repeat
biolog
plausibl
associ
clinic
marker
lung
diseas
suitabl
use
outcom
measur
multicentr
clinic
trial
studi
provid
rational
mean
test
intervent
aim
prevent
structur
lung
diseas
young
children
cf
introductionaim
microrna
express
profil
interest
biomark
tuberculosi
tb
effect
antitb
therapi
mirna
profil
pulmonari
tb
patient
unknown
examin
studi
method
plasma
mirna
level
mirna
compar
tb
patient
match
healthi
control
china
mirna
differenti
regul
two
group
ten
analys
test
cohort
pulmonari
tb
patient
sampl
prior
commenc
antibiot
therapi
one
two
six
month
treatment
result
six
mirna
differenti
express
test
group
tb
patient
mir
upregul
whilst
mir
downregul
combin
mirna
distinguish
pulmonari
tb
healthi
control
sensit
specif
auc
within
one
month
treatment
signific
modul
mir
seen
success
treat
patient
although
mirna
return
baselin
complet
treatment
six
mirna
differenti
express
test
group
tb
patient
mir
upregul
whilst
mir
downregul
combin
introductionaim
recent
advanc
implic
airway
epithelium
key
driver
asthma
pathogenesi
partli
due
dysregul
respons
damag
novel
therapi
focus
protect
repair
vulner
airway
particularli
earli
life
could
transform
asthma
treatment
prevent
diseas
developmentprogress
analys
primari
airway
epitheli
cell
paec
migrat
pattern
postwound
invitro
identifi
mechan
potenti
therapeut
target
enhanc
wound
repair
process
method
paec
obtain
nonasthmat
asthmat
paediatr
airway
scratch
wound
perform
paec
monolay
assess
repair
imag
everi
minut
incucyt
essen
bioscienc
migrat
trajectori
leadingedg
paec
analys
use
imagej
integrin
gene
protein
express
investig
qpcr
western
respect
total
rna
sequenc
illumina
differenti
geneexpress
analysi
perform
ingenu
system
qiagen
result
respons
wound
asthmat
children
defici
lack
specif
significantli
lower
mean
migrat
distanc
nonasthma
asthma
meanaesem
veloc
direction
forward
migrat
index
major
regul
cell
migrat
ie
integrin
investig
paec
lower
gene
p
p
protein
p
p
level
paec
asthmat
children
compar
control
rnaseq
analysi
identifi
differenti
express
gene
asthmat
children
rel
control
overrepres
gene
ontolog
relat
integrin
extracellular
matrix
drug
databas
screen
identifi
sever
clinic
safe
drug
examin
drug
repurpos
potenti
restor
integrin
express
aid
wound
repair
novel
experi
demonstr
abnorm
migrat
behaviour
asthmat
airway
epithelium
postwound
mechan
control
diseas
phenomenon
identifi
like
decreas
integrin
multipl
transcript
mechan
dysregul
asthmat
target
exist
drug
support
airway
epitheli
repair
barrier
integr
may
novel
therapeut
avenu
asthma
simul
synergist
effect
viru
infect
allergen
exposur
asthma
suscept
mice
expos
low
dose
pneumonia
viru
mous
pvm
low
dose
cockroach
antigen
cre
earli
life
later
life
four
week
final
cre
exposur
mice
inocul
rhinoviru
dexamethason
administ
intraperiton
twiceweek
cre
rv
challeng
daili
euthanasia
necessari
diseas
onset
progress
level
elev
immedi
follow
final
cre
exposur
persist
airway
time
challeng
mice
coexpos
pvmcre
cre
pvm
alon
present
eosinophil
inflamm
increas
number
type
innat
lymphoid
cell
mucou
hypersecret
elev
level
follow
rv
infect
treatment
dexamethason
attenu
type
inflamm
effect
mucou
product
critic
dexamethason
promot
express
antivir
cytokin
acceler
viral
clearanc
obstruct
pulmonari
diseas
copd
known
complic
prognost
potenti
prevent
time
transit
palli
care
thu
primari
respons
care
provis
remain
famili
person
copd
aim
explor
experi
older
peopl
live
stage
iv
copd
rural
commun
copd
influenc
relationship
ident
method
eleven
older
peopl
stage
iv
copd
live
region
nsw
undertook
narr
interview
discuss
copd
journey
interview
transcrib
analys
interpret
accord
hermeneut
phenomenolog
methodolog
result
spousal
care
gener
well
accept
expect
marri
particip
extens
marit
role
howev
adult
children
involv
care
decis
make
particip
express
guilt
frustrat
perceiv
actual
burden
place
selfperceiv
burden
ground
experi
care
love
one
flow
effect
uptak
cope
treatment
strategi
advanc
care
plan
acp
well
creat
commun
barrier
parti
parent
aim
protect
adult
children
distress
impact
live
prioritis
children
wish
whilst
simultan
undercommun
need
diseas
specif
inform
paradox
mani
particip
went
design
acp
refus
treatment
rather
extend
impact
children
live
contrari
children
acp
request
protect
adult
children
primari
determin
end
life
decis
make
critic
establish
formal
effect
commun
pathway
famili
health
profession
facilit
good
death
within
famili
group
conclus
analysi
among
first
examin
combin
biomark
assess
respons
omalizumab
saa
patient
suggest
subgroup
combin
increas
ige
eo
may
experi
greater
clinic
benefit
howev
caution
must
use
interpret
result
given
posthoc
natur
conclus
vcd
present
third
patient
difficult
asthma
vcd
associ
femal
sex
poorer
asthma
outcom
despit
better
lung
function
improv
lung
function
poorer
qualiti
life
independ
predictor
vcd
find
highlight
import
identifi
address
vcd
challeng
patient
group
genotyp
shown
predict
respons
inhal
steroid
mild
asthma
gene
signatur
sputum
cell
clc
alpl
distinguish
asthma
inflammatori
phenotyp
aim
determin
gene
express
signatur
endobronchi
biopsi
adult
asthma
relat
asthma
sever
airway
inflammatori
phenotyp
method
nonsmok
adult
asthma
current
respiratori
symptom
evid
variabl
airflow
obstruct
asthma
sever
defin
accord
gina
inflammatori
phenotyp
use
bal
cell
count
gene
analyz
qpcr
use
extract
rna
result
biopsi
evalu
sever
asthma
mild
moder
asthma
differ
age
sex
atopi
smoke
histori
group
gene
express
significantli
increas
sever
compar
mildmoder
asthma
invers
associ
fev
predict
particip
asthma
gene
express
clc
significantli
increas
eosinophil
asthma
compar
paucigranulocyt
asthma
respect
alpl
increas
eosinophil
compar
mixedgranulocyt
asthma
gene
express
clc
associ
asthma
bal
eosinophil
gene
express
increas
neutrophil
compar
paucigranulocyt
asthma
significantli
associ
bal
neutrophil
result
rsv
infect
ovasensitisedchalleng
balbc
mice
result
significantli
increas
ahr
macrophag
neutrophil
lung
infiltr
exacerb
accompani
increas
level
inflammatori
cytokin
includ
kc
compar
uninfect
ovatr
mice
ovatr
mice
expos
uvinactiv
rsv
dexamethason
treatment
complet
inhibit
featur
allerg
diseas
includ
ahr
eosinophil
infiltr
uninfect
ovasensitisedchalleng
mice
convers
dexamethason
treatment
follow
rsvinduc
exacerb
partial
suppress
ahr
fail
dampen
macrophag
neutrophil
infiltr
inflammatori
cytokin
product
kc
mimic
clinic
observ
patient
exacerb
associ
increas
neutrophil
often
poorli
respond
corticosteroid
therapi
interestingli
also
observ
increas
level
sputum
sampl
neutrophil
asthmat
patient
rsvinduc
exacerb
resist
steroid
treatment
inhibit
function
deplet
macrophag
suppress
featur
diseas
includ
ahr
macrophag
neutrophil
infiltr
find
highlight
critic
role
macrophag
inflammatori
cytokin
includ
viralinduc
exacerb
asthma
suggest
examin
pathway
novel
therapeut
approach
diseas
manag
unchang
level
significantli
increas
cftr
mutant
compar
aec
supernat
baselin
aec
line
demonstr
signific
increas
product
follow
fac
challeng
preliminari
pathway
analys
proteom
data
reveal
signific
differenti
express
protein
involv
oxid
stress
mitochondri
stress
respons
compar
aec
airway
epithelium
cf
demonstr
abnorm
iron
regul
exhibit
proinflammatori
phenotyp
activ
cell
pathway
involv
oxid
stress
result
spirometri
measur
avail
mean
age
year
total
cfct
score
year
greater
median
significantli
associ
shorten
time
result
seventeen
infant
cf
median
age
month
interquartil
rang
iqr
month
male
homozyg
nine
control
infant
median
age
month
iqr
month
male
contribut
bal
sampl
divers
reduc
cf
compar
control
bal
sampl
median
shannon
divers
index
iqr
iqr
respect
firmicut
preval
phylum
group
accout
total
read
respect
howev
staphylococcu
predomin
cf
sampl
total
read
next
preval
genera
cf
sampl
streptococcu
haemophilu
granulicatella
gemella
contrast
five
abund
genera
control
sampl
streptococcu
fusobacterium
neisseria
gemella
introductionaim
six
minut
walk
test
object
tool
use
assess
function
exercis
capac
cystic
fibrosi
cf
howev
relationship
outcom
need
hospitalis
treatment
pulmonari
exacerb
pe
studi
therefor
primari
aim
determin
relationship
six
minut
walk
distanc
subject
breathless
modifi
borg
score
oxygen
satur
p
frequenc
durat
hospitalis
adult
cf
theodora
ahila
present
right
compens
worker
occup
lung
diseas
theodora
discuss
legal
entitl
flow
diagnosi
occup
lung
diseas
differ
legal
statutori
entitl
follow
differ
state
togeth
complex
assess
claim
particularli
presenc
comorbid
introductionaim
littl
known
mani
australian
expos
potenti
hazard
agent
workplac
lifetim
assess
exposur
statu
use
current
job
data
miss
earlier
exposur
potenti
longterm
effect
account
chang
occup
exposur
time
analysi
determin
proport
nation
populationbas
sampl
australian
adult
everexpos
potenti
hazard
agent
work
life
method
individu
recruit
telephon
particip
studi
control
nation
sampl
idiopath
pulmonari
fibrosi
ipf
case
australia
individu
match
age
sex
state
consent
particip
complet
telephon
interview
collect
data
includ
demograph
selfreport
environment
exposur
detail
occup
histori
report
job
code
finnish
job
exposur
matrix
finjem
assign
associ
exposur
relev
time
period
particip
consid
expos
agent
job
probabl
exposur
data
job
particip
occup
histori
collat
assess
lifetim
exposur
statu
descript
statist
conduct
assess
proport
everexpos
respir
dust
anim
dust
iron
plant
dust
asbesto
environment
tobacco
smoke
mould
quartz
dust
silica
analysi
selfreport
occup
exposur
data
yield
higher
proport
dusti
environ
gasesfumeschem
asbesto
silica
expect
significantli
male
expos
femal
agent
p
consider
number
older
australian
expos
potenti
harm
agent
within
work
life
data
lifetim
occup
exposur
requir
examin
potenti
occup
risk
factor
diseas
ipf
aim
aim
determin
impact
communitysampl
geogen
dust
pm
particul
matter
diamet
immort
human
airway
epitheli
cell
particular
aim
determin
effect
nontyp
haemophilu
influenza
nthi
infect
geogen
dust
collect
remot
town
western
australia
pm
extract
cell
expos
pm
pb
vitro
addit
live
moi
trypan
blue
stain
use
determin
cell
viabil
bacteri
infect
attach
invas
determin
use
gentamicin
surviv
assay
epitheli
releas
assess
use
bead
base
immunoassay
result
pretreat
cell
dust
pm
significantli
increas
abil
nthi
attach
invad
cell
p
respect
dust
exposur
respons
increas
respons
suppress
human
airway
cell
may
contribut
common
sever
respiratori
infect
import
implic
lung
health
individu
live
arid
environ
remot
australia
expos
high
load
geogen
dust
introductionaim
australian
aborigin
children
much
higher
incid
infecti
diseas
nonaborigin
counterpart
mani
aborigin
commun
expos
high
level
ambient
dust
geogen
earthderiv
origin
previous
report
associ
selfreport
dust
exposur
poor
health
remot
aborigin
commun
aim
studi
examin
associ
selfreport
dust
exposur
infecti
diseas
aborigin
children
child
health
survey
waach
link
ehn
odd
ratio
associ
health
outcom
exposur
calcul
use
multivari
logist
regress
model
within
multilevel
framework
take
account
hierarch
structur
data
result
preliminari
result
highlight
difficulti
diagnosi
coal
worker
pneumoconiosi
although
data
collect
ongo
radiolog
grade
major
case
date
low
grade
ilo
addit
case
seri
highlight
earli
stage
coal
worker
present
soft
ground
glass
nodul
low
densiti
therefor
extrem
difficult
detect
plain
radiograph
case
progress
massiv
fibrosi
coal
exposur
alon
clinic
occup
histori
predict
diagnosi
patient
symptomat
cough
strong
occup
histori
dust
exposur
queensland
worker
occup
histori
heavi
dust
exposur
usual
symptomat
radiograph
chang
often
subtl
particularli
plain
radiograph
introductionaim
assess
commun
health
impact
shortterm
particl
exposur
event
eg
fire
difficult
one
approach
involv
collect
particl
sampl
roofspac
expos
dwell
proxi
particl
gener
exposur
event
follow
studi
fire
collect
particl
ceil
hous
differ
distanc
particl
sourc
use
mous
model
aim
determin
whether
utero
exposur
particl
alter
postnat
lung
function
method
mous
dam
intranas
expos
ceil
particl
salin
carbon
black
particl
control
salin
alon
gestat
day
e
two
week
age
lung
volum
tgv
lung
mechan
airway
resist
raw
tissu
damp
g
tissu
elast
h
measur
anaesthetis
tracheostomis
mice
use
plethysmographi
forc
oscil
techniqu
fot
respect
effect
utero
exposur
ceil
dust
carbon
particl
tgv
mice
femal
p
male
p
similarli
effect
exposur
particl
raw
femal
p
male
p
g
femal
p
male
p
howev
effect
femal
p
male
mice
expos
ceil
dust
p
carbon
p
higher
h
magnitud
respons
associ
distanc
particl
sourc
utero
exposur
particl
ceil
dust
increas
lung
stiff
male
mice
data
suggest
exposur
ceil
dust
may
impact
lung
growth
sex
specif
manner
respons
appear
unrel
rel
contamin
ceil
dust
particl
combust
sourc
introductionaim
steroidresist
asthma
major
unmet
need
asthma
manag
effect
treatment
urgent
requir
howev
develop
hamper
lack
understand
pathogen
mechan
involv
increas
bodi
evid
show
high
fat
diet
hfd
andor
obes
associ
steroidresist
asthma
howev
precis
mechan
involv
remain
unclear
studi
show
hfdinduc
obes
caus
increas
airway
hyperrespons
ahr
mice
respons
driven
inflammasomemedi
respons
howev
whether
hfdobes
affect
steroid
respons
whether
therapeut
inhibit
inflammasom
effect
treatment
hfdobesityinduc
experiment
asthma
unknown
develop
novel
mous
model
hfdobes
combin
establish
model
ovalbumininduc
steroid
sensit
allerg
airway
diseas
aad
effect
steroid
treatment
role
potenti
target
respons
lung
hfdobesityinduc
aad
examin
use
therapeut
treatment
dexamethason
potent
highli
select
inhibitor
show
hfd
result
signific
increas
adipos
weight
gain
significantli
hfdobes
induc
increas
eosinophil
number
lung
steroidresist
ahr
absenc
presenc
aad
also
show
hfd
result
increas
stain
airway
epithelium
well
signific
increas
activ
whole
lung
tissu
significantli
treatment
suppress
hfdobesityinduc
steroidresist
ahr
absenc
presenc
aad
develop
novel
murin
model
hfdinduc
obes
induc
steroidresist
aad
also
identifi
previous
unrecognis
role
hfdobesityinduc
inflammasomemedi
respons
lung
develop
steroidresist
aad
thu
hfdobes
induc
increas
inflammasom
respons
lung
may
therapeut
target
treatment
steroidresist
asthma
show
respiratori
infect
suppress
induct
airway
epithelium
aad
associ
increas
level
free
h
ion
bronchoalveolar
lavag
treatment
nahco
infectioninduc
ssiaad
suppress
steroidresist
ahr
complementari
gainoffunct
studi
administr
acetazolamid
carbon
anhydras
inhibitor
steroidsensit
aad
mimic
effect
decreas
respons
induc
steroid
resist
ahr
promot
ra
ssraad
introductionaim
electron
cigarett
ecigarett
heat
aerosolis
liquid
produc
inhal
aerosol
often
contain
nicotin
flavour
littl
known
potenti
impact
healthhowev
research
indic
increas
airway
resist
healthi
asthmat
individu
may
facilit
asthma
attack
aim
assess
effect
ecigarett
use
lung
function
earli
late
phase
asthmat
respons
epr
lpr
respect
mice
without
exist
ovalbumininduc
allerg
airway
diseas
assess
volum
lung
function
use
plethysmographi
forcedoscil
techniqu
asthmat
adult
femal
balbc
mice
minut
minut
acut
ecigarett
aerosol
exposur
also
measur
airway
hyperrespons
ahr
second
group
mice
hour
minut
aerosol
exposur
four
type
ecigarett
test
epr
studi
acut
ecigarett
exposur
littl
effect
lung
function
except
mice
expos
vegetableglycerin
vapour
exhibit
immedi
temporari
impair
lung
function
littl
differ
asthmat
nonasthmat
mice
lpr
studi
previou
ecigarett
exposur
exacerb
function
asthmat
respons
protect
effect
nicotin
free
ecigarett
vapour
inflamm
studi
sensitis
challeng
ovalbumin
increas
ahr
cellular
inflamm
exacerb
eosinophilia
neutrophilia
ecigarett
expos
asthmat
mice
studi
show
acut
ecigarett
aerosol
exposur
limit
effect
respiratori
health
mous
model
allerg
airway
diseas
ecigarett
aerosol
exposur
neg
protect
effect
respiratori
health
appar
depend
type
ecigarett
excipi
inform
avail
caution
exercis
advoc
ecigarett
safe
altern
tobacco
smoke
especi
asthmat
introductionaim
idiopath
pulmonari
fibrosi
ipf
fatal
lung
diseas
unknown
etiolog
occur
predominantli
elderli
mechan
link
age
persist
accumul
lung
fibroblast
lf
ipf
remain
incomplet
understood
fibroblast
senesc
character
growth
arrest
apoptosi
resist
senescenceassoci
secretori
phenotyp
sasp
occur
age
may
contribut
ipf
aim
studi
character
senesc
human
lf
vitro
ascertain
role
mitochondri
dysfunct
acquisit
andor
reinforc
senesc
phenotyp
method
ipflf
line
establish
lung
tissu
ipf
patient
compar
lf
agematch
control
ctrllf
cell
prolifer
telomer
length
sasp
cytokin
product
senescentassoci
activ
level
assess
cell
count
pcr
elisa
cytochemistri
immunoblot
respect
increas
level
mitochondri
dna
superoxid
featur
mitochondri
dysfunct
evalu
pcr
mitosox
fluorogen
dye
respect
rotenon
use
disrupt
mitochondri
activ
result
ipflf
display
slower
growth
accompani
decreas
level
cellular
protein
telomer
length
compar
ctrllf
p
convers
ipflf
resist
h
cytox
ctrllf
p
ipflf
also
exhibit
increas
activ
sasp
cytokin
product
level
p
furthermor
ipflf
lower
level
mitochondriadriven
protein
bax
higher
level
mitochondri
dna
superoxid
product
ctrllf
rotenon
increas
mitochondri
superoxid
ctrllf
preced
increas
marker
senesc
studi
suggest
ipflf
exhibit
senesc
like
featur
includ
replic
arrest
resist
oxid
stressinduc
cytox
induct
sasp
mitochondri
dysfunct
tightli
link
senesc
like
contribut
heal
repair
malfunct
lf
ipf
introductionaim
report
defect
efferocytosi
associ
cigarett
smoke
andor
airway
inflamm
chronic
lung
diseas
includ
chronic
obstruct
pulmonari
diseas
sever
asthma
also
show
defect
phagocytosi
nontyp
h
influenza
nthi
common
colon
lower
airway
copd
defect
could
substanti
overcom
lowdos
azithromycin
howev
chronic
usag
may
induc
bacteri
resist
investig
two
novel
macrolid
erythromycylamin
azithromycinbas
molecul
significantli
diminish
antibiot
activ
aureu
pneumonia
catarrhali
h
influenza
nthi
flow
cytometri
secret
cleav
intracellular
cba
immunofluoresc
confoc
microscopi
test
primari
alveolar
macrophag
macrophag
ae
cigarett
smoke
extract
respect
macrophag
viabil
remain
follow
exposur
either
macrolid
concentr
secret
intracellular
cleav
decreas
macrolid
signific
chang
recognit
molecul
mertk
particul
cytoplasm
immunofluoresc
inflammasom
also
significantli
reduc
conclud
may
use
reduc
airway
inflamm
chronic
lung
diseas
without
induc
bacteri
resist
effect
h
vc
express
surfact
protein
number
surfact
produc
cell
present
lung
tissu
show
effect
chronic
fetal
hypoxemia
molecular
program
oxid
stress
airway
remodel
lung
earli
adulthood
matern
antenat
antioxid
treatment
protect
offer
insight
mechan
possibl
treatment
improv
offspr
respiratori
outcom
introduct
iron
essenti
mani
biolog
process
much
littl
iron
result
wide
varieti
patholog
alter
iron
level
andor
dysregul
iron
homeostasi
associ
number
lung
diseas
includ
chronic
obstruct
pulmonari
diseas
lung
cancer
cystic
fibrosi
howev
mechan
underpin
associ
whether
iron
play
role
pathogenesi
lung
diseas
yet
fulli
elucid
determin
effect
system
iron
overload
iron
level
lung
assess
effect
increas
iron
lung
structur
function
function
assess
transferrin
receptor
tfr
mutant
mice
wildtyp
wt
balbc
mice
fed
carbonyl
iron
diet
compar
wt
normal
diet
control
respect
effect
increas
iron
load
murin
model
bleomycininduc
fibrosi
hous
dust
mite
hdm
induc
allerg
airway
diseas
aad
also
assess
genet
dietinduc
model
iron
overload
increas
iron
level
lung
associ
emphysemalik
alveolar
enlarg
small
airway
collagen
deposit
alter
baselin
lung
function
increas
airway
hyperrespons
ahr
whilst
iron
overload
absenc
bleomycin
administr
result
gener
fibrosi
small
airway
ahr
similar
level
observ
bleomycininduc
fibrosi
iron
overload
minim
addit
effect
combin
bleomycin
iron
overload
also
result
increas
eosinophil
inflamm
sever
ahr
hdminduc
aad
conclus
data
show
increas
iron
level
lung
result
emphysema
airway
fibrosi
correspond
reduc
lung
function
model
use
better
understand
role
iron
pathogenesi
lung
diseas
fibros
interstiti
pneumonia
unknown
caus
median
surviv
year
previous
shown
dysregul
activ
transcript
factor
character
function
differ
subset
fibroblast
presenc
correl
ipf
progress
question
drive
phenotyp
diverg
cell
prolong
lifespan
remain
unansw
hypothesi
activ
transcript
factor
increas
fibrot
lung
tissu
ipf
patient
contribut
senesc
via
role
cytokin
express
mitochondri
dysfunct
aim
work
evalu
whether
role
senesc
lung
fibroblast
lf
ipf
method
primari
cultur
lf
establish
lung
tissu
ipf
patient
ipflf
control
donor
ctlf
senesc
induc
expos
cell
hydrogen
peroxid
h
hr
activ
assess
differ
passag
follow
h
immunoblot
senesc
evalu
measur
activ
product
express
cellcycl
arrest
protein
mitochondri
superoxid
product
assess
use
mitosox
flourogen
assay
inhibit
pharmacolog
inhibitor
transfect
sirna
method
electrocardiogram
assess
tachycardia
atrial
fibril
right
left
ventricular
hypertrophi
ischaem
chang
patient
chest
radiograph
assess
sign
heart
failur
patient
assess
done
two
independ
examin
blind
cardiac
biomark
statu
associ
abnorm
least
moder
interrat
agreement
high
cardiac
biomark
ntprobnp
troponin
highsensit
analys
result
high
ntprobnp
valu
associ
atrial
fibril
vs
right
ventricular
hypertrophi
vs
left
ventricular
hypertrophi
vs
ischaemia
vs
electrocardiogram
cardiomegali
vs
chest
radiograph
high
troponin
valu
associ
tachycardia
vs
right
ventricular
hypertrophi
vs
ischaem
chang
vs
electrocardiogram
none
test
sensit
specif
biochem
indic
cardiac
dysfunct
bestperform
indic
ntprobnp
ischaem
chang
sensit
specif
troponin
best
indic
tachycardia
ischaem
chang
sensit
specif
respect
associ
abnorm
cardiac
biomark
may
indic
cardiac
diseas
patient
exacerb
copd
howev
electrocardiogram
chest
radiograph
poor
sensit
specif
diagnos
acut
cardiac
dysfunct
set
cardiac
biomark
provid
addit
inform
acut
cardiac
dysfunct
patient
exacerb
copd
research
fund
heart
foundat
new
zealand
rd
lead
caus
chronic
morbid
death
worldwid
cigarett
smoke
major
caus
copd
develop
countri
current
therapi
limit
efficaci
fail
halt
diseas
progress
caus
advers
side
effect
effect
treatment
urgent
requir
howev
develop
hamper
lack
understand
mechan
promot
pathogenesi
diseas
function
microrna
mir
health
diseas
firmli
establish
aberr
express
associ
sever
lung
diseas
includ
copd
studi
aim
identifi
mir
promot
develop
copd
assess
therapeut
potenti
target
mir
identifi
perform
mir
microarray
analys
lung
mice
expos
highli
repres
cigarett
smoke
cs
induc
model
experiment
copd
identifi
one
highest
upregul
mir
role
potenti
target
csinduc
lung
examin
use
treatment
specif
inhibitor
antagomir
result
lung
express
increas
throughout
cs
exposur
experiment
copd
reduc
lung
function
human
copd
patient
correl
lung
express
treatment
inhibit
csinduc
lung
express
suppress
airway
inflamm
small
airway
fibrosi
improv
lung
function
experiment
copd
silico
analys
identifi
potenti
axi
put
target
neg
regul
known
induc
activ
significantli
cs
exposur
decreas
lung
model
treatment
restor
level
decreas
express
activ
identifi
previous
unrecognis
pathogen
role
axi
experiment
copd
data
highlight
novel
therapeut
target
treatment
copd
tlco
featur
emphysema
pulmonari
hypertens
ct
quantifi
emphysema
via
emphysema
index
ei
addit
pulmonari
arteri
distens
pad
known
correl
mean
pulmonari
arteri
pressur
measur
right
heart
catheteris
measur
simultan
use
ecggat
ct
impact
pulmonari
arteri
distens
relationship
fev
emphysema
index
ei
tlco
never
examin
aim
studi
determin
effect
pad
fev
ei
tlco
hypothesi
addit
pad
data
would
help
account
variabl
tlco
unexplain
two
paramet
method
patient
analys
cohort
prospect
group
patient
recruit
year
period
acut
exacerb
copd
subsequ
ecg
gate
ct
pulmonari
function
test
perform
stabl
period
exclud
patient
miss
data
signific
motion
artefact
ct
unabl
perform
tlco
patient
enter
multipl
linear
regress
model
tlco
correct
haemoglobin
enter
depend
variabl
order
ei
pad
enter
regress
model
independ
variabl
overal
model
abl
explain
variat
tlco
correct
r
ei
significantli
correl
tlco
control
variabl
r
p
ei
r
p
howev
control
ei
pad
significantli
correl
tlco
r
p
emphysema
index
significantli
neg
correl
tlco
control
variabl
addit
pad
data
appear
add
analysi
introductionaim
preval
chronic
obstruct
pulmonari
diseas
copd
use
spirometri
cirteria
extens
studi
howev
littl
evid
exist
use
transfer
factor
carbon
monoxid
tlco
diagnosi
classif
copd
guidelin
global
initi
chronic
obstruct
lung
diseas
gold
current
utilis
spirometri
predomin
aid
physiciandiagnosi
copd
sinc
rel
small
proport
smoker
develop
copd
aim
assess
tlco
serv
use
earli
biomark
detect
lung
diseas
younger
smoker
normal
spirometri
perform
crosssect
analysi
subject
spirometri
tlco
measur
respiratori
laboratori
monash
lung
sleep
monash
health
subject
includ
male
femal
age
year
normal
spirometri
least
packyear
smoke
histori
one
hundr
six
subject
age
normal
spirometri
signific
smoke
histori
identifi
cohort
subject
group
tlco
lower
limit
normal
use
at
criteria
cohort
equal
divid
male
low
tlco
femal
low
tlco
fibrinogen
combin
thrombin
fibrin
sealant
indic
use
adjunct
haemostasi
patient
undergo
surgeri
control
bleed
convent
surgic
techniqu
ineffect
impract
wide
use
gener
surgic
procedur
remain
nonstandard
approach
manag
haemoptysi
recent
case
report
describ
effect
usag
massiv
haemoptysi
techniqu
bronchial
embolis
bronchoscop
suction
surgic
resect
fail
may
ineffect
howev
tisseel
use
independ
endoscopi
migrat
dislodg
even
expector
fibrin
clot
common
complic
lead
recurr
haemoptysi
present
first
ever
report
case
success
endobronchi
use
tisseel
control
activ
distal
bronchial
bleed
year
old
ladi
suffer
ongo
haemoptysi
secondari
recurr
non
small
cell
lung
cancer
involv
later
segment
left
lower
lobe
underw
therapeut
bronchoscopi
utilis
therapeut
video
scope
olympu
introduc
via
rigid
bronchoscop
provid
secur
airway
access
identifi
sourc
bleed
tisseel
inject
distal
size
spirat
ibv
insert
add
stabil
prevent
expector
fibrin
clot
ml
tisseel
inject
proxim
top
valv
excel
seal
procedur
resolut
bleed
method
patient
select
establish
criteria
multidisciplinari
patient
underw
ebv
insert
first
month
program
one
patient
complet
post
procedur
lung
function
exclud
chang
residu
volum
rv
total
lung
capac
tlc
rel
chang
calcul
patient
test
done
prior
ebv
insert
compar
three
month
post
procedur
follow
minim
clinic
import
differ
mcid
use
assess
object
respons
patient
also
underw
clinic
review
ascertain
subject
chang
wellb
rel
increas
mean
p
decreas
mean
residu
volum
p
decreas
mean
tlc
ml
p
follow
ebv
insert
regard
minim
clinic
import
differ
patient
cohort
greater
volum
reduct
rv
wherea
patient
cohort
rel
increas
one
patient
pneumothorax
follow
valv
insert
one
nine
patient
valv
migrat
requir
reposit
patient
subject
respons
first
clinic
review
post
valv
insert
one
patient
longer
requir
home
oxygen
audit
demonstr
subject
object
benefit
ebv
insert
care
select
patient
symptomat
emphysema
best
current
manag
program
success
public
hospit
set
local
support
case
nsclc
no
patient
underw
pet
scan
report
consist
primari
lung
lesion
nodal
metastasi
malign
case
discuss
multidisciplinari
case
confer
patient
peripher
lung
nodul
hilar
mediastin
lymph
node
enlarg
ebu
tbna
effect
method
provid
diagnosi
stage
avoid
addit
procedur
use
combin
patholog
pet
give
convinc
evid
nodal
diseas
peripher
lung
lesion
lesion
identifi
radial
endobronchi
ultrasound
ebu
imag
characteris
benign
versu
malign
aetiolog
previous
report
analys
expert
defin
regionofinterest
roi
correctli
classifi
lesion
posit
predict
valu
ppv
howev
main
limit
studi
restrict
roi
maximum
pixel
aim
studi
assess
whether
unconstrain
roi
select
result
larger
portion
lesion
analys
would
improv
result
nguyen
et
al
studi
utilis
use
custom
written
imag
analysi
softwar
expert
physician
identifi
unconstrain
polygon
roi
follow
greyscal
featur
calcul
mean
maximum
minimum
maximum
minimum
standard
deviat
entropi
contrast
correl
energi
homogen
mannwhitney
u
test
use
compar
featur
receiveroper
characterist
roc
curv
gener
optim
cutoff
point
determin
malign
versu
benign
differenti
sensit
specif
accuraci
ppv
calcul
result
malign
benign
case
five
greyscal
textur
featur
maximum
maximum
minimum
mean
standard
deviat
entropi
significantli
differ
malign
benign
group
maximum
maximum
minimum
standard
deviat
areaund
roc
curv
respect
optim
cutoff
valu
maximum
pixel
valu
sensit
specif
ppv
malign
maximum
minimum
pixel
valu
sensit
specif
ppv
standard
deviat
sensit
specif
ppv
maximum
greyscal
pixel
valu
highest
diagnost
accuraci
perform
singlecentr
audit
patient
known
nsclc
pet
scan
also
underw
ebustbna
explicitli
state
purpos
pulmonari
lymph
node
stage
combin
bronchoscopi
report
patholog
report
imag
report
chart
review
use
identifi
patient
inform
result
overal
case
identifi
exclud
due
incomplet
collect
date
pet
demonstr
case
low
intermedi
grade
bilater
lymph
node
uptak
case
unilater
lymph
node
uptak
two
case
pet
uptak
case
bilater
uptak
case
ebustbna
sampl
posit
malign
two
case
subsequ
upstag
posit
nodal
involv
underw
surgeri
case
unilater
nodal
involv
pet
scan
frequenc
biobsi
posit
malign
ebustbna
subsequ
underw
surgeri
dust
inhal
seen
biopsi
specimen
patient
bilater
pet
uptak
patient
unilater
pet
uptak
case
seri
also
add
grow
bodi
evid
dust
inhal
associ
pet
posit
although
symmetr
uptak
pet
scan
technic
repres
diseas
ebustbna
surgeri
demonstr
low
rate
posit
lymph
node
metastas
highlight
role
ebustbna
rule
patient
surg
rather
exclud
pet
find
alon
lifesav
strategi
acut
respiratori
distress
syndrom
ard
lead
ventilatorinduc
lung
injuri
vili
increas
morbid
mortal
despit
decad
research
progress
design
ventil
strategi
prevent
vili
limit
part
due
inabl
assess
region
respons
mechan
ventil
aim
studi
use
novel
noninvas
xray
imag
approach
quantifi
region
respons
mechan
ventil
explor
impact
tidal
volum
region
heterogen
vili
mice
imag
use
laboratori
xray
sourc
acquisit
synchronis
ventil
obtain
imag
imag
postprocess
use
xray
velocimetri
combin
quantit
ct
obtain
region
volum
data
tidal
volum
frc
situ
result
qualit
tissu
expans
contour
imag
data
show
substanti
region
variat
tidal
stretch
group
respons
mechan
ventil
global
hour
ventil
mice
protect
strategi
signific
chang
tidal
volum
sd
n
p
frc
sd
n
p
contrast
mice
injuri
strategi
decreas
tidal
volum
sd
n
p
decreas
frc
sd
n
p
preliminari
result
promis
show
clear
region
variat
distens
ventil
group
quantit
data
possibl
region
lobar
sublobar
basi
imag
technolog
focu
ongo
work
result
investig
lead
better
understand
vili
result
improv
outcom
critic
ill
patient
requir
mechan
ventil
sever
asthma
howev
respons
treatment
highdos
highfin
particl
fraction
inhal
corticosteroidlong
act
beta
agonist
icslaba
combin
yet
establish
aim
measur
effect
fluticasoneeformoterol
ventil
heterogen
measur
multipl
breath
nitrogen
washout
clinic
outcom
addit
aim
determin
predictor
improv
conduct
scond
acinar
sacin
ventil
heterogen
hypothesis
chang
highdos
fluticasoneeformoterol
would
improv
scond
sacin
along
clinic
improv
asthma
control
method
patient
male
doctor
diagnosi
asthma
uncontrol
compon
asthma
control
questionnair
score
current
ic
icslaba
maximum
fluticason
equival
enrol
baselin
scond
sacin
exhal
nitric
oxid
feno
airway
hyperrespons
ahr
methacholin
log
dose
respons
slope
log
dr
spirometri
measur
patient
took
ii
bd
fluticasoneeformoterol
via
spacer
week
repeat
test
relationship
chang
scond
sacin
baselin
ahr
spirometri
feno
examin
result
associ
ventil
heterogen
ahr
slow
resolv
antiinflammatori
treatment
mechan
poorli
understood
aim
studi
determin
antiinflammatori
treatment
reduc
heterogen
bronchoconstrict
measur
low
ventil
area
vspectct
investig
role
peripher
airway
heterogen
mechan
method
twentyon
asthmat
subject
femal
mean
ae
sd
age
ae
yr
ae
pred
baselin
methacholin
challeng
vspectct
scan
week
combin
icslaba
treatment
low
ventil
measur
chang
ventil
volum
two
threshold
vspect
ratio
dose
respons
slope
dr
calcul
measur
ahr
report
logdr
multipl
breath
nitrogen
washout
perform
baselin
treatment
determin
peripher
ventil
heterogen
sacin
result
analys
use
pair
ttest
linear
regress
conclus
antiinflammatori
treatment
reduc
heterogen
bronchoconstrict
measur
function
lung
imag
reduct
develop
low
ventil
area
challeng
treatment
predict
pretreat
airway
hyperrespons
peripher
heterogen
improv
treatment
relat
imag
bronchoconstrict
pattern
imag
difficult
quantifi
potenti
could
give
valuabl
mechanist
insight
futur
treatment
improv
increas
ventilatori
drive
hyperventilatori
respons
characteris
worsen
breath
effici
increas
v
e
vco
lower
end
tidal
co
p
et
co
rest
exercis
whilst
timecours
chang
hyperventilatori
respons
wellcharacterist
acclim
climber
date
littl
examin
respons
ascent
return
altitud
larg
group
nonacclim
climber
aim
current
studi
examin
chang
ga
exchang
measur
group
nonacclim
climber
ascent
mt
kilimanjaro
immedi
return
altitud
kilimanjaro
climb
exercis
test
step
test
gasexchang
complet
four
occas
follow
altitud
basecamp
p
b
mmhg
mmhg
mmhg
return
base
camp
p
b
mmhg
result
ascent
subject
becam
increasingli
hypox
decreas
nadir
p
exercis
nadir
p
exercis
breath
effici
worsen
v
e
vco
p
et
co
fell
p
et
co
mmhg
subject
ascend
return
altitud
p
normalis
p
howev
persist
evid
hyperventil
breath
effici
p
et
co
remain
abnorm
exercis
v
e
vco
p
et
co
mmhg
p
vs
rest
high
altitud
exposur
increas
ventilatori
drive
follow
high
altitud
exposur
p
normalis
ga
exchang
remain
alter
hypothesis
alter
ga
exchang
may
due
sustain
alkalosi
central
chemoreceptor
remain
reset
defend
lower
pco
establish
high
altitud
exposur
patient
pneumothorax
follow
ttnb
either
admit
observ
vs
requir
chest
drain
record
includ
durat
hospit
admiss
patient
requir
chest
drain
defin
poor
toler
pneumothorax
chi
squar
test
use
determin
associ
age
preexist
copd
smoke
histori
comorbid
reduc
lung
function
dlco
poor
toler
pneumothorax
result
total
ttnb
procedur
carri
procedur
complic
pneumothorax
patient
requir
aspir
chest
drain
mean
length
stay
lo
day
procedur
poor
toler
pneumothorax
averag
predict
sd
averag
dlco
predict
sd
ie
moder
reduc
patient
patient
requr
chest
drain
copd
chi
squar
test
show
statist
signific
associ
copd
poor
toler
pneumothorax
statist
signific
associ
older
patient
year
poor
toler
pneumothorax
reduc
lung
function
poor
toler
pneumothorax
presenc
copdhav
reduc
lung
functionold
age
poor
toler
pneumothorax
neg
studi
howev
limit
small
number
larger
studi
look
risk
factor
crucial
prevent
unneccessari
lengthi
hospit
stay
chest
drain
insert
caus
routin
ttnb
procedur
nil
declar
interest
introductionaim
endobronchi
ultrasound
guid
sheath
ebusg
use
locat
biopsi
peripher
lung
lesion
sensit
specif
respect
minim
data
regard
combin
convent
transbronchi
lung
biopsi
ctblb
plu
ebusg
biopsi
approach
patient
aim
assess
util
approach
assess
complic
rate
result
patient
elig
mean
sd
age
year
male
mean
sd
lesion
size
mm
patient
lesion
success
localis
use
ebusg
lesion
concentr
eccentr
data
miss
remain
ebusg
biopsi
posit
patient
definit
atyp
pattern
seen
patient
give
cumul
sensit
brush
via
guid
sheath
posit
patient
ctblb
definit
posit
patient
atyp
cytolog
pattern
seen
patient
give
cumul
sensit
use
non
gs
guid
procedur
standard
brush
posit
patient
four
patient
diagnos
base
ctblb
alon
ebusg
guid
investig
neg
combin
ctblb
ebusg
procedur
increas
sensit
one
small
pneumothorax
manag
conserv
one
episod
bleed
requir
local
adrenalin
therapi
ebu
gs
provid
higher
success
rate
diagnosi
peripher
lung
lesion
ctblb
howev
ebusg
combin
ctblb
may
increas
diagnost
yield
lusw
novel
techniqu
assess
surfac
lung
tissu
elast
properti
measur
surfac
wave
propag
speed
use
ultrasound
detector
system
surfac
wave
propag
lung
noninvas
gener
local
small
mechan
actuat
skin
chest
wallsinc
mani
interstiti
diseas
predominantli
affect
lung
peripheri
may
especi
suitabl
type
assess
noninvas
without
radiat
exposur
method
healthi
control
patient
ct
chest
identifi
peripher
distribut
pulmonari
fibrosi
studi
lusw
perform
gener
small
second
harmon
vibrat
hz
indent
mm
area
intercost
space
handheld
shaker
measur
surfac
wave
propag
lung
ultrasound
probe
place
mm
away
intercost
space
three
measur
full
inspir
made
locat
lung
result
measur
made
hz
msecaesd
conclus
result
suggest
lusw
identifi
differ
wave
speed
control
abnorm
peripher
fibrot
lung
reproduc
specif
sensit
abil
detect
longitudin
chang
yet
defin
promis
advantag
noninvas
radiationfre
grant
support
nih
nation
heart
lung
blood
institut
conclus
chines
individu
osa
uniqu
sleep
phenotyp
compar
caucasian
characteris
high
arous
threshold
increas
cycl
period
chemoreflex
delay
reflect
propens
longer
respiratori
event
data
suggest
mechan
caus
osa
influenc
ethnic
use
sed
rais
arous
threshold
may
less
effect
treat
osa
chines
popul
lack
understand
host
immun
diseas
mechan
respiratori
infect
cov
studi
characteris
innat
immun
respons
differenti
primari
bronchial
epitheli
cell
pbec
infect
relat
less
virul
method
human
pbec
obtain
subject
brush
bronchoscopi
cell
grown
air
liquid
interfac
ali
differenti
cilia
beat
mucu
product
observ
day
cell
infect
multipl
infect
moi
hour
day
supernat
total
cell
protein
extract
rna
collect
time
point
measur
express
proinflammatoryand
antiviralcytokin
viru
replic
result
demonstr
differ
viral
replic
kinet
replic
earlier
effici
peak
hour
associ
activ
innat
host
respons
induct
type
interferon
ifn
stimul
gene
viperin
contrast
replic
peak
later
hour
day
viru
demonstr
attenu
level
viperin
begun
investig
virul
factor
control
epitheli
respons
cov
sequenc
analysi
viral
protein
embo
needl
reveal
ident
match
highlight
potenti
variat
host
epitheli
viru
interact
studi
demonstr
replic
differenti
pbec
induc
diverg
innat
immun
respons
potenti
link
differ
replic
kinet
understand
hostviru
interact
less
virul
coronavirus
give
insight
pathogen
mechan
underpin
sarscov
merscovinduc
respiratori
diseas
mortal
morbid
literatur
suggest
bacteri
coinfect
complic
influenza
case
contribut
sever
prolong
cours
ill
challeng
clinic
practic
remain
identif
patient
benefit
empir
antibiot
method
retrospect
audit
patient
influenza
infect
diagnos
viral
nasopharyng
swab
gchh
juli
septemb
demograph
clinic
microbiolog
data
complic
outcom
collect
data
antibiot
prescript
also
collect
patient
without
bacteri
coinfect
compar
result
patient
diagnos
influenza
infect
viral
nasopharyng
swab
bacteri
coinfect
present
patient
common
coinfect
bacteri
pathogen
staphylococcu
aureu
streptococcu
pneumonia
pseudomona
aeruginosa
chronic
lung
diseas
copd
associ
significantli
higher
risk
bacteri
coinfect
p
comorbid
examin
includ
activ
smoke
activ
malign
chronic
cardiovascular
diseas
endstag
renal
failur
diabet
mellitu
immunosuppress
immunocompromis
state
achiev
statist
signific
patient
microbiolog
find
bacteri
coinfect
receiv
antibiot
prescript
antibiot
group
patient
result
signific
differ
inhospit
mortal
inhospit
mortal
lengthofstay
icu
admiss
significantli
higher
patient
bacteri
coinfect
compar
without
although
mortal
similar
two
group
incid
bacteri
coinfect
cohort
patient
lower
anticip
find
suggest
probabl
overus
antibiot
group
patient
may
benefit
empir
treatment
antibiot
chronic
lung
diseas
copd
prospect
studi
develop
score
system
could
help
identifi
patient
would
benefit
empir
antibiot
conclus
first
studi
develop
lung
function
trajectori
childhood
middl
age
gener
popul
identifi
three
trajectori
increas
risk
copd
acceler
lung
declin
adulthood
low
initi
lung
function
childhood
normal
growth
normal
declin
low
initi
lung
function
childhood
reduc
growth
acceler
declin
import
modifi
childhood
risk
factor
three
trajectori
includ
exposur
matern
smoke
childhood
lack
exclus
breast
feed
earli
life
strategi
maxim
lung
function
growth
earli
life
well
prevent
acceler
declin
import
copd
prevent
rftc
introduct
biphas
initi
patient
ct
scan
first
specialist
assess
fsa
phase
two
month
biopsi
incorpor
bronchoscopi
ctguid
biopsi
ultrasoundguid
biopsi
rftc
phase
patient
suspect
lung
cancer
identifi
decemb
may
prior
rftc
phase
time
diagnost
pathway
measur
compar
phase
may
juli
juli
octob
median
time
use
statist
analysi
patient
underw
long
wait
person
clinic
reason
therebi
distort
data
result
investig
suspect
lung
cancer
preval
age
normal
distribut
peak
prefer
lower
socioeconom
decil
equal
gender
proport
ethnic
distribut
endobronchi
ultrasound
ebu
utilis
biopsi
method
follow
bronchoscopi
time
gp
referr
fsa
phase
improv
significantli
p
similarli
time
fsa
diagnosi
treatment
improv
significantli
median
time
reduc
p
day
p
respect
phase
tabl
appoint
first
consult
hospit
specialist
gp
referr
date
referr
specialist
gener
practition
diagnosi
date
diagnosi
biopsi
report
date
ct
report
date
biopsi
taken
treatment
day
treatment
chemotherapi
radiotherapi
surgeri
best
support
care
discuss
rtfc
significantli
shorten
time
diagnosi
treatment
popul
best
knowledg
first
studi
demonstr
reduct
time
treatment
lung
cancer
patient
nz
fast
track
clinic
previou
studi
use
ebu
initi
investig
result
faster
treatment
seem
improv
surviv
ebu
could
easili
incorpor
rftc
model
may
confer
surviv
advantag
method
prospect
studi
consecut
patient
lung
malign
mf
ratio
mean
ae
year
ebustbna
perform
use
median
aspir
olympu
needl
smear
cell
block
tumour
cell
abund
assess
experienc
cytopathologist
scale
absent
abund
genom
dna
isol
smear
block
quantifi
sequenc
use
truseq
amplicon
cancer
panel
illumina
san
diego
ca
miseq
platform
diff
quik
slide
digit
scan
use
dna
exract
result
unexpectedli
overal
cellular
higher
cytolog
slide
cell
block
case
score
tumour
cell
abund
compar
cell
block
p
chisquar
test
case
provid
adequ
dna
amplicon
sequenc
ng
highest
dna
yield
cell
block
cytolog
slide
respect
mean
standard
deviat
sd
dna
yield
cell
block
ng
ng
cytolog
slide
ng
ng
differ
significantli
p
pair
ttest
extract
dna
good
qualiti
exhibit
dna
fragment
size
agaros
gel
conclus
diffquik
stain
cytolog
slide
present
numer
advantag
ffpe
cell
block
sourc
dna
molecular
patholog
includ
increas
dna
yield
immedi
visual
confirm
adequ
malign
cell
sampl
